| Date | Quarter | Session | EPS (est → actual) | Revenue (est → actual) |
|---|---|---|---|---|
| Oct 29, 2026Next | Q3 2026 | — | 1.74 | 12.7 B |
Sep 1, 2026
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceuticals stocks fared in Q2, starting with Bristol-Myers Squibb (NYSE:BMY).
Aug 31, 2026
The deaths of three study participants led Novartis to halt development of rap-cel in multiple indications, while “transient” side effects led Bristol Myers to voluntarily pause its zola-cel program.
Even though Bristol-Myers Squibb (currently trading at $66.44 per share) has gained 6.6% over the last six months, it has lagged the S&P 500’s 12.3% return during that period. This might have investors contemplating their next move.
Bristol Myers Squibb (NYSE:BMY) today presented results from the EXPLORER-LTE cohort of the MAVA-LTE study (NCT03723655) in a late-breaker presentation at the European Society of Cardiology (ESC) Congress 2026 in
Aug 29, 2026
PRINCETON, N.J., August 29, 2026--Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten)....
Bristol Myers Squibb is facing down a major patent cliff, which is a problem and a huge motivating force.
Bristol-Myers Squibb has delivered a strong 47.9% return over the past year, yet several valuation checks still frame the stock as cheap relative to an intrinsic value estimate and to market multiples. For investors, the question is whether the current share price reflects a genuine discount or simply the market catching up with earlier pessimism. The 47.9% gain over 1 year highlights how sharply sentiment toward Bristol-Myers Squibb has improved. This can reduce the margin of safety if...
CAR-T therapies are transforming treatment for certain cancers and raising hopes for patients. Several approved therapies have delivered strong responses for patients with advanced blood cancers where conventional treatments have failed. It’s no wonder the CAR-T market is expanding rapidly. The global CAR-T therapy market is projected to grow from $2.69 billion in 2022 to […]
Aug 28, 2026
On August 13, two pharmaceutical companies tied to the same cardiovascular research deal delivered major updates. Atrium Therapeutics, Inc. (NASDAQ:RNA) earned a $15 million milestone payment from Bristol-Myers Squibb Company (NYSE:BMY) after delivering a lead RNA compound targeting an undisclosed cardiology indication. The payment stems from a global collaboration eligible to yield Atrium up to […]
Bristol-Myers Squibb Company (NYSE:BMY) has ended its partnership with cell-therapy manufacturer Cellares after determining that Cellares’ Cell Shuttle platform could not meet the requirements needed to manufacture Breyanzi at commercial scale. The partnership, announced in 2024, was valued at up to $380 million and was intended to expand Breyanzi manufacturing capacity across the U.S., Europe, […]
The U.S. FDA has approved Bristol-Myers Squibb Company (NYSE:BMY)’s oral blood-cancer drug iberdomide, sold as Zenbexus, for patients with relapsed or refractory multiple myeloma. The treatment is given with Johnson & Johnson’s Darzalex and dexamethasone. The approval gives BMY another product that could support growth in its oncology business. Iberdomide belongs to a newer class […]
Aug 27, 2026
BMY's Camzyos gains momentum as an adolescent expansion nears an FDA decision, while rivals advance competing heart drugs.
